1 / 8

Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery

Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery. Nancy A. Nussmeier, M.D., Andrew A. Whelton, M.D., Mark T. Brown, M.D., Richard M. Langford, F.R.C.A., Andreas Hoeft, M.D., Joel L. Parlow, M.D., Steven W. Boyce, M.D. and Kenneth M. Verburg, Ph.D. N Engl J Med

meena
Download Presentation

Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery Nancy A. Nussmeier, M.D., Andrew A. Whelton, M.D., Mark T. Brown, M.D., Richard M. Langford, F.R.C.A., Andreas Hoeft, M.D., Joel L. Parlow, M.D., Steven W. Boyce, M.D. and Kenneth M. Verburg, Ph.D. N Engl J Med Volume 352;11:1081-1091 March 17, 2005

  2. Study Overview • When administered to patients for pain control after coronary-artery bypass surgery, valdecoxib and its intravenous prodrug, parecoxib, were found to be associated with an increased risk of cardiovascular thromboembolic events • These findings add to the growing concern that the use of COX-2 inhibitors increases the risk of cardiovascular events, particularly in persons who are at risk for such events

  3. Enrollment and Outcome Nussmeier, N. et al. N Engl J Med 2005;352:1081-1091

  4. Preoperative Characteristics of All Randomized Patients Nussmeier, N. et al. N Engl J Med 2005;352:1081-1091

  5. Characteristics of the Surgical Procedures Nussmeier, N. et al. N Engl J Med 2005;352:1081-1091

  6. Incidence of and Risk Ratios for Predefined Adverse Events and Death among Patients Who Received the Assigned Treatment Nussmeier, N. et al. N Engl J Med 2005;352:1081-1091

  7. Kaplan-Meier Estimates of the Time to a Cardiovascular Event Nussmeier, N. et al. N Engl J Med 2005;352:1081-1091

  8. Conclusions • The use of parecoxib and valdecoxib after CABG was associated with an increased incidence of cardiovascular events, arousing serious concern about the use of these drugs in such circumstances

More Related